news
Targeting channel in cell lysosome could selectively kill cancer cells
Activating the protein channel TRPML1 induced selective melanoma cell death while sparing normal cells, suggesting a potential pathway for new cancer therapies.
List view / Grid view
Cell-based assays
webinar
Cardiac proarrhythmic risk assessment using human-induced pluripotent stem cell-derived cardiomyocytes
19 August 2021 | By Eurofins Discovery
Watch this on-demand webinar that discusses the two assays developed by Eurofins and why they represent a more physiologic and dynamic system to provide a more comprehensive pre-clinical model for cardiac liability assessment.
news
Scientists manipulate water droplets to create biochemical reactors
Researchers have developed a new method that manipulates tiny water droplets in lab-on-chip applications for cell culturing and drug screening.
article
New models for intranasal drug delivery
In this article, Dr Jon Volmer and Dr Jon Lenn discuss a new approach to formulation models to test drug delivery based on reconstituted nasal epithelium.
news
Inhibiting PIP4K enzymes could help immune system fight cancer
Researchers identified a potential therapeutic involving the inhibition of PIP4K enzymes which could enable the immune system to destroy tumour cells.
news
Screening method finds potential drugs to repurpose against COVID-19
Researchers have identified 38 drugs that could be repurposed to treat COVID-19 through a strategy involving virtual screening and cell-based assays.
article
Making cell culture models more physiologically relevant
A major limitation in drug development is the occurrence of drug-candidate toxicity during clinical research. This may occur because tumour-derived cell lines are limited as a pre-clinical model – in part because of an altered metabolic poise. A recent study has revealed a profound plasticity in gene expression and metabolic poise that can…
webinar
Automating functional cell-based bioassays: assay reproducibility and performance for potency testing programmes
28 May 2021 | By Eurofins DiscoverX* and Tecan
In this on-demand webinar, we discuss how Eurofins DiscoverX’s off-the-shelf, MOA-based functional, cellular assays address these challenges, enabling drug discovery programmes up to late-stage development and market release.
news
Cell-based assays market set to exhibit CAGR of 8.5 percent
The global cell-based assays market is expected to grow due to increasing investments into cell-based research and a rise in chronic diseases.
article
COVID-19 drug targets and cell-based assays
The length of time between the administration of a COVID-19 vaccine and evidence of a robust immune response to Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) means that treatments are still required. In this article, Sheraz Gul and Alp Tegin Sahin explore the various therapeutic targets that have been identified…
article
Drug Target Review Assays ebook 2021
In this ebook, find articles exploring some of the assays used to identify the most promising COVID-19 drugs and discussing the development of a novel assay to reveal potential peptide therapeutics for cancer.
news
Cell-based assays market set to be worth $22bn by 2025
New research has shown that the cell-based assays market will grow at a CAGR of 8.1 percent between 2020 and 2025.
news
Cell-based assay developed to identify IDO1 inhibitors for immuno-oncology
Researchers have developed a cell-based assay for the discovery of new IDO1 inhibitors, overcoming challenges from cell-free assays.
news
Nanolitre‐scale cell assays developed with droplet microarray-mass spec
A team has developed nanolitre cell assays on droplet microarrays to enable pharmacodynamic monitoring in live cells.
news
Novel enterocyte-like cells developed by researchers from stem cells
A team has developed enterocyte-like cells from hiPSCs, which can be used to study the absorption of novel oral drugs.
